Spinogenix is a clinical-stage biopharma company aiming to change how we treat brain diseases by focusing on restoring — rather than simply slowing the loss of — synaptic connections in the brain. Their lead therapy, SPG302 (recently named tazbentetol), is an oral, once-daily small molecule designed to trigger the formation of new glutamatergic synapses, potentially reversing cognitive and motor decline in diseases like Alzheimer’s disease, Amyotrophic lateral sclerosis (ALS) and Schizophrenia. Beyond SPG302, the company is also developing another candidate, SPG601, aimed at correcting synaptic dysfunction in Fragile X syndrome — a leading inherited form of intellectual disability. Backed by grants from major funding bodies, Spinogenix’s “synaptic regenerative” approach could open a new frontier in neurodegenerative and neuropsychiatric treatment.